13054.02320 FID BOX SGA

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Arthur LANDER, et al.

Serial No:

09/807,575

Filed:

July 12, 2001

For: GLYPICAN FOR THE DETECTION AND

TREATMENT OF HUMAN CARCINOMA

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS **CONTAINING NUCLEOTIDE SEQUENCE AND/OR** AMINO ACID SEQUENCE DISCLOSURES

Box Sequence **US PTO** PO Box 2327 Arlington, VA 22202 Art Unit:

(Not Assigned)

Examiner:

(Not Assigned)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed

Commissioner for Patents Washington D.C. 20231, on

March 21, 2003

Date of Deposit Heather B. Del Bosco

Name

Signature

03/21/03

Date

Dear Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures," dated March 3, 2003 enclosed please find a CD-ROM copy and a hardycopy of the requested corrected Sequence Listing are enclosed for your review.

Please charge any insufficiency or credit any overpayment to Deposit Account No. 50 2567. A copy of this document is enclosed.

IN THE SPECIFICATION:

Kindly enter the attached 'Sequence Listing" into the specification of the above referenced application and delete any "Sequence listing" that may already exist within the specification.

REMARKS

A corrected substitute CRF CD ROM and a paper version of the "Sequence Listing" are provided herewith. Applicants hereby state that the contents of the CRF CD ROM and the paper version CRF are

identical. Further, this submission is made to correct errors in the previous submissions of this Sequence Listing. No new matter has been added.

The present CRF diskette has been examined with Checker 3.1 which reported that there were no errors in the listing.

Respectfully submitted,

REED SMITH CROSBY HEAFEY

Date: March 21, 2003

Stefan J. Kirchanski U Registration No. 36,568 Attorney for Applicant(s)

1901 Avenue of the Stars, Suite 700

Los Angeles, CA 90067 Phone: (310) 734-5200

Fax: (310) 734-5299

10/16/1998



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

09/807,575

Arthur Lander

RECEIVED

I.A. FILING DATE

PRIORITY DATE

MAR 2 0 2003

28983 REED SMITH CROSBY HEAFEY LLP 1901 AVENUE OF THE STARS, SUITE 700 LOS ANGELES, CA 90067

CONFIRMATION NO. 9101
371 FORMALITIES LETTER
OC0000000009585920

10/15/1999

Date Mailed: 03/04/2003

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Diskette
- Copy of the International Application
- · Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination
- Small Entity Statement

Applicant's response filed 07/12/2001 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 09/14/2001 have not been completed.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

 The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

ANITA D JOHNSON

Telephone: (703) 305-3661

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/807,575	PCT/US99/24176	82351.0003

FORM PCT/DO/EO/916 (371 Formalities Notice)